1. Home
  2. BILL vs NAMS Comparison

BILL vs NAMS Comparison

Compare BILL & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BILL Holdings Inc.

BILL

BILL Holdings Inc.

HOLD

Current Price

$47.88

Market Cap

3.2B

Sector

Technology

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$26.91

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BILL
NAMS
Founded
2006
2019
Country
United States
Netherlands
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.7B
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
BILL
NAMS
Price
$47.88
$26.91
Analyst Decision
Buy
Strong Buy
Analyst Count
21
8
Target Price
$57.90
$46.75
AVG Volume (30 Days)
2.6M
1.1M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.81
EPS
N/A
N/A
Revenue
$1,653,160,000.00
$22,503,000.00
Revenue This Year
$14.18
$17.96
Revenue Next Year
$13.83
$540.65
P/E Ratio
N/A
N/A
Revenue Growth
13.03
N/A
52 Week Low
$31.41
$23.05
52 Week High
$57.21
$42.21

Technical Indicators

Market Signals
Indicator
BILL
NAMS
Relative Strength Index (RSI) 55.81 39.13
Support Level $46.72 $25.88
Resistance Level $49.60 $37.29
Average True Range (ATR) 2.04 1.13
MACD -0.45 0.17
Stochastic Oscillator 26.67 34.98

Price Performance

Historical Comparison
BILL
NAMS

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: